GlassScriptPhysician profile
Jonathan Shammash
NPI 1518055896
$964.17
in general payments reported to CMS, 2019-2025
21 companies · $60.65 in 2025
The $60.65 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $59.61 · 2021: $129 · 2022: $210 · 2023: $196 · 2024: $133 · 2025: $60.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $136.11 | 2021-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $127.80 | 2022-2023 | Freestyle Libre, Freestyle Libre 3 |
| Lilly USA, LLC | $118.40 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $70.84 | 2021-2024 | |
| Daiichi Sankyo INC. | $66.73 | 2020-2022 | |
| Exact Sciences Corporation | $62.96 | 2023-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $52.97 | 2019-2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.43 | 2021-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $46.15 | 2022-2024 | Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $42.28 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $33.10 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $24.25 | 2019 | |
| Corcept Therapeutics | $16.68 | 2024 | Korlym |
| Dynavax Technologies Corporation | $16.47 | 2025 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.07 | 2023 | Xifaxan, Trulance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $15.23 | 2019 | |
| Gilead Sciences, INC. | $14.72 | 2020 | |
| Vyera Pharmaceuticals, LLC | $14.67 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.64 | 2023 | Farxiga |
| Sobi, INC | $14.46 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Shammash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.